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randomized controlled trials have questioned 
the beneficial impact revealed by previous ob‑
servational and interventional studies.1‑3 It was 
shown that type 2 diabetes (T2D) could reduce 
this positive effect, at least in patients with es‑
tablished atherosclerotic CVD.5‑8 Since then, 
there have been conflicting reports on the asso‑
ciation between n‑3 PUFAs and cardiovascular 
events.4,9‑11 A systematic review of randomized 
IntroductIon Previous landmark studies 
revealed the beneficial effect of n‑3 polyunsatu‑
rated fatty acids (PUFAs) in patients with stable 
atherosclerotic cardiovascular disease (CVD).1‑4 
Serum concentrations of n‑3 PUFAs were shown 
to be inversely correlated with all‑cause mortali‑
ty, independently of cardiovascular risk factors.4 
However, with the improvement in optimal car‑

















Background Recent improvements in optimal cardiovascular therapy have questioned the beneficial 
effects of polyunsaturated fatty acids (PUFAs) observed in previous studies.
aims We investigated the fatty acid (FA) composition in serum phospholipids in patients with an established 
acute phase of myocardial infarction (MI) and in high ‑risk patients with stable atherosclerotic cardiovascular 
disease (CVD).
methods We studied 83 patients hospitalized within 12 hours from the onset of the first clinical symptoms 
of MI. As a control group, we assessed 74 patients at high cardiovascular risk with an established stable 
atherosclerotic CVD treated at an outpatient cardiology clinic. Gas chromatography was used to evaluate 
the FA composition in serum phospholipids in both groups.
results The final analysis included 52 patients with acute MI and 74 controls. In both groups, saturated 
FAs constituted the largest fraction of serum phospholipid FAs (median, 1574.67 μmol/l), followed by n‑6 
PUFAs (median, 1106.99 μmol/l). The levels of total saturated FAs, monounsaturated FAs, n‑6 PUFAs, 
as well as the ratio of n‑6 to n‑3 PUFAs significantly differed between groups. Palmitic acid constituted 
the largest fraction of serum phospholipids both in patients and controls (31.9% and 31.16%, respectively). 
In a multivariate logistic regression analysis, body mass index, low ‑density lipoprotein cholesterol, 
aspartate aminotransferase, high ‑sensitivity C ‑reactive protein, and palmitoleic and eicosadienoic acids 
were independently associated with MI.
conclusions We showed major differences in the FA composition of serum phospholipids between 
patients with acute MI and high ‑risk individuals with stable atherosclerotic CVD. Eicosadienoic and 
palmitoleic acids, apart from typical cardiovascular risk factors, were independently associated with MI.
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Control group The control group included 74 pa‑
tients with established stable atherosclerotic 
CVD and T2D treated at an outpatient cardiol‑
ogy clinic. The exclusion criteria were as follows: 
acute coronary syndrome (within the previous 
3 months), percutaneous coronary intervention 
or coronary artery bypass grafting (within the 
previous month). Other exclusion criteria were 
identical to those in the MI group.
The  study was approved by the  local eth‑
ics committee (no., KBET 122.6120.271.2015 
and 122.6120.92.2015). Each patient provided 
written informed consent before enrollment 
to the study.
Laboratory investigations Blood samples 
were obtained on admission to the emergen‑
cy department (MI group), or between 8 AM 
and 10 AM on admission to the department af‑
ter overnight fasting (control group). The sam‑
ples were processed 30 to 60 minutes after 
blood collection and stored at −70°C until fur‑
ther analysis. Blood was taken from the ante‑
cubital vein with minimal stasis. Routine blood 
tests, including the measurement of complete 
blood count, lipid profile (total cholesterol [TC], 
 low ‑density   lipoprotein cholesterol [LDL ‑C], 
high ‑density lipoprotein cholesterol [HDL ‑C], 
and triglycerides), and the levels of aspartate 
aminotransferase, alanine transaminase, and 
serum creatinine, were done by automated lab‑
oratory techniques. Glycated hemoglobin A1c lev‑
els were measured using a turbidimetric inhibi‑
tion immunoassay.
Analysis of fatty acid composition in serum phos-
pholipids The analytical procedure consist‑
ed of a few separate steps: 1) extraction of se‑
rum total lipids; 2) separation of the lipid frac‑
tion on Sep ‑PakNH2 columns (Waters, Milford, 
Massachusetts, United States); 3) methylation 
and separation of the FA from the phospholip‑
id fraction by gas chromatography (6890N Net‑
work GC Systems, Agilent Technologies, Wilm‑
ington, Delaware, United States) equipped with 
an Agilent J&W HP‑88 capillary column (100 m, 
0.250 mm, 0.20 μm) (Agilent Technologies). 
As an internal standard, 1,2‑dipentadecanoil‑
‑sn ‑glicero‑3‑phosphocholine was used (Sigma‑
‑Aldrich, Steinheim, Germany). The method 
was calibrated using a calibration mixture (all 
FAs, Sigma ‑Aldrich). The serum levels of satu‑
rated FAs (SFAs) (lauric, C12:0; myristic, C14:0; 
palmitic, C16:0; stearic, C18:0; and lignoceric, 
C24:0) and unsaturated acids (n‑7 [palmitoleic 
(POA), C16:1], n‑9 [oleic, C18:1], n‑3 [α ‑linolenic 
(ALA), C18:3; EPA, C20:5; and DHA, C22:6], 
and n‑6 [linoleic (LA), C18:2; eicosadienoic 
(EDA), C20:2; and arachidonic (AA), C20:4] of 
the phospholipid fraction were quantitative‑
ly measured by gas chromatography. The se‑
rum concentration of FAs of the phospholipid 
controlled trials did not find any significant ef‑
fects of n‑3 PUFAs on mortality or cardiovascular 
events.12 However, a recently published REDUCE‑
‑IT study (Reduction of Cardiovascular Events 
with Icosapent Ethyl ‑Intervention Trial) brought 
our attention to the proper dosage of eicosapen‑
taenoic acid (EPA) ethyl ester in high ‑risk patients 
with established atherosclerotic CVD or T2D, and 
demonstrated a significant reduction of cardio‑
vascular mortality.13,14 Therefore, we sought to in‑
vestigate the differences in fatty acid (FA) compo‑
sition in serum phospholipids between patients 
with an established acute phase of myocardial 
infarction (MI) and high ‑risk patients with sta‑
ble atherosclerotic CVD, and to assess the pre‑
dictive value of these FAs in the diagnosis of MI.
Methods study population Myocardial in-
farction group We assessed 83 patients hos‑
pitalized within 12 hours from the onset of 
the first clinical symptoms of MI. We includ‑
ed both patients with ST ‑segment elevation MI 
(STEMI) and those with non–ST ‑segment eleva‑
tion MI (NSTEMI). The inclusion criteria were 
the diagnosis of STEMI or NSTEMI and age of 45 
years or older. Both STEMI and NSTEMI diagno‑
ses were established according to the Third Uni‑
versal Definition of Myocardial Infarction.15‑23 
The exclusion criteria were as follows: prior n‑3 
PUFA treatment, known sensitivity or allergy to 
fish or PUFA supplements (or other conditions 
resulting in the lack of dietary intake of n‑3 or 
n‑6 PUFAs), pregnancy, active bleeding, acute 
infection, serum creatinine levels higher than 
177 μmol/l (2 mg/dl), liver injury (alanine trans‑
aminase levels >1.5 times above the upper lim‑
it of the reference range), alcohol or drug abuse, 
history of malignancy (unless disease free for >10 
years or nonmelanoma skin carcinoma), life ex‑
pectancy of less than 12 months due to concom‑
itant diseases, abnormal laboratory or imaging 
findings that would interfere with the interpre‑
tation of the results, and any life ‑threatening 
condition during the study.
whAt’s new?
The beneficial effects of polyunsaturated fatty acids (PUFAs) observed in 
previous landmark studies have been questioned by recent improvements 
in optimal cardiovascular therapy. We investigated the fatty acid (FA) composition 
in serum phospholipids in patients in the acute phase of myocardial infarction 
(MI) and patients at high cardiovascular risk with established atherosclerotic 
cardiovascular disease, using gas chromatography. The levels of total saturated 
FAs, monounsaturated FAs, n‑6 PUFAs, and the ratio of n‑6 to n‑3 PUFAs were 
significantly higher in the MI group. Interestingly, there were no significant 
differences in n‑3 PUFA levels. A multivariate analysis demonstrated that 
palmitoleic and eicosadienoic acids (together with other factors such as body 
mass index, low ‑density lipoprotein cholesterol, aspartate aminotransferase, 
high ‑sensitivity C ‑reactive protein) were independently associated with MI, 
which is a novel finding.
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Fatty acid composition in serum phospholip-
ids Saturated FAs constituted the largest frac‑
tion of serum phospholipid FAs both in the MI 
and control groups (median, 1574.67 μmol/l [IQR, 
1402.43–1855.81 μmol/l] and 1441.56 μmol/l 
[IQR, 1282.93–1599.76 μmol/l], respectively), 
followed by n‑6 PUFAs as the second (median, 
1106.99 μmol/l [IQR, 986.84–1264.19 μmol/l] 
and median, 1004.72 μmol/l [IQR, 877.78–
1118.32 μmol/l], respectively). Interesting‑
ly, in the MI group, the third major fraction 
of serum phospholipids were monosaturated 
FAs (MUFAs) (median, 348.48 μmol/l [IQR, 
299.82–443.54 μmol/l]), while in the control 
group, n‑3 PUFAs (median, 359.11 μmol/l [IQR, 
280.13–425.70 μmol/l]).
Significant differences between the MI and 
control groups were found for every type of 
the FA fraction of serum phospholipids, in‑
cluding SFAs, MUFAs, n‑3 PUFAs, and n‑6 PU‑
FAs (TAble 3). Importantly, total SFAs, MUFAs, n‑6 
PUFA, as well as the ratio of n‑6 to n‑3 PUFAs 
significantly differed between groups (FIGUre 1A–1G), 
while there were no significant differences in 
DHA and EPA concentrations.
Considering single FAs, palmitic acid consti‑
tuted the largest fraction of serum phospholipids: 
31.9% and 31.16% in the MI and control groups, 
respectively. In the MI group, LA and AA were 
the second and third largest fractions of serum 
phospholipids (16.4% and 15.8%, respectively). 
In the control group, AA was the second largest 
fraction, while LA constituted the third largest 
fraction (17.6% and 14.4%, respectively) (TAble 3).
univariate and multivariate logistic regres-
sion analyses Significant predictors of MI 
in the study population are presented in TAble 4. 
The multivariate logistic regression analysis dem‑
onstrated that body mass index, LDL ‑C, aspar‑
tate aminotransferase, hs ‑CRP, POA (C16:1), and 
EDA (C20:2) were independently associated with 
MI (TAble 4). The predictive model showed a high 
degree of cross ‑validated calibration and dis‑
crimination, with an area under the curve of 0.99.
dIscussIon In our study, we demonstrated 
that patients with MI had significantly increased 
concentrations of total n‑6 PUFAs, total SFAs, 
total MUFAs, and an increased ratio of n‑6 to n‑3 
PUFAs when compared with patients with stable 
atherosclerotic CVD. Furthermore, to the best 
of our knowledge, this is the first study to show 
that the concentrations of POA (MUFA) and EDA 
(n‑6 PUFA) are independent predictors of MI. 
We found that higher concentrations of both 
FAs, together with known cardiovascular risk 
factors such as LDL ‑C and hs ‑CRP levels, were 
significantly associated with MI.
It was previously shown that the FA compo‑
sition of serum phospholipids is dependent on 
fraction was expressed as μmol/l. All laborato‑
ry tests were performed by investigators blind‑
ed to the sample origin.
statistical analysis Categorical variables were 
presented as numbers and percentages. Continu‑
ous variables were expressed as mean (SD) or me‑
dian and interquartile range (IQR). Differences 
between groups were compared using the Stu‑
dent or Welch t test, depending on the equali‑
ty of variances for normally distributed vari‑
ables. The Mann–Whitney test was used for 
nonnormally distributed continuous variables. 
Normality was assessed by the Shapiro–Wilk 
test. The equality of variances was assessed us‑
ing the Levene test. Categorical variables were 
compared by the Fisher exact test for 2×2 ta‑
bles or by the Pearson χ2 test for other tables. 
The Pearson correlation coefficient was computed 
to measure the linear dependence between 2 nor‑
mally distributed variables. The Spearman rank 
correlation coefficient was calculated to measure 
monotonic trends between 2 variables if the dis‑
tribution of the variables was nonnormal.
All baseline characteristics, as well as labo‑
ratory investigations and fatty acid concentra‑
tions, were assessed as potential predictors of 
MI using a univariate logistic regression analy‑
sis. If a P value from simple logistic regression 
for a specific variable was 0.15 or lower, the vari‑
able was included in a multiple logistic regres‑
sion model. Two ‑sided P values of less than 0.05 
were considered significant. All calculations were 
done with JMP, version 14.0.0 (SAS Institute Inc., 
Vienna, Austria, 2018). 
In cases of possibility of separation problems in 
logistic regression, the Firth bias‑adjusted meth‑
od was used. This maximum likelihood–based 
method has been shown to produce better esti‑
mates and tests than maximum likelihood–based 
models that do not use bias correction. In addi‑
tion, bias correction ameliorates separation prob‑
lems that tend to occur in logistic‑type models.
resuLts baseline characteristics The final 
analysis included 52 patients in the MI group 
and 74 controls. The baseline characteristics 
of the study patients, including comorbidities 
and medication use, are shown in TAble 1. We did 
not observe any differences in age, sex, current 
smoking status, prior MI, hypertension, and 
chronic kidney disease between groups. Howev‑
er, the percentage of patients with obesity, T2D, 
and use of antidiabetic medication was higher 
in the MI than in the control group (TAble 1). In 
addition, as expected, there were significant 
differences between groups in high ‑sensitivity 
C ‑reactive protein (hs ‑CRP) levels, lipid profile 
(TAble 2), left ventricular ejection fraction, as well 
as the use of some of the drugs, for example, 
clopidogrel or acetylsalicylic acid (TAble 1).
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Table 1 Characteristics of patients with myocardial infarction, controls with stable atherosclerotic cardiovascular disease, and the whole 
study population
Variable MI group (n = 52) Control group (n = 74) Total population (n = 126) P value
Age, y, mean (SD) 67.98 (11.67) 65.58 (6.84) 66.57 (9.18) 0.19
Male sex 36 (69.23) 48 (64.86) 84 (66.67) 0.61
Weight, kg 81.5 (70–90) 90.20 (81.05–100) 87 (75.1–98) 0.001
Waist circumference, cm, mean (SD) 99.76 (14.64) 106 (9.66) 103.48 (12.26) 0.01
BMI, kg/m2 27.40 (25.19–31) 31.00 (27.83–33.30) 29.90 (26.55–32.85) 0.001
Previous MI 12 (23.08) 9 (25) 21 (23.86) 0.84
Obesity 24 (46.15) 43 (58.11) 67 (53.17) 0.02
Current smoking 17 (32.69) 4 (21.05) 21 (29.58) 0.34
Type 2 diabetes 19 (36.54) 74 (100) 93 (73.81) 0.001
Hypertension 47 (90.38) 62 (83.78) 109 (86.51) 0.29
Hypercholesterolemia 50 (96.15) 50 (67.57) 100 (79.37) 0.001
Hypertriglyceridemia 6 (11.54) 27 (36.49) 33 (26.19) 0.002
Heart failure 31 (62) 6 (31.58) 37 (53.62) 0.02
Chronic kidney disease 11 (21.15) 9 (12.16) 20 (15.87) 0.17
Left ventricular ejection fraction, % 48 (40–55) 60 (50–62.8) 50 (45–60) 0.001
Systolic BP, mm Hg 142.5 (128.75–163) 140 (130–150) 140 (130–155.25) 0.39
Diastolic BP, mm Hg 86 (78.25–94.75) 80 (75–86.25) 84.5 (75–90) 0.046
Medication
β ‑Blocker 42 (80.77) 59 (79.73) 101 (80.16) 0.89
ACEI 43 (82.69) 50 (67.57) 93 (73.81) 0.06
ARB 4 (7.69) 16 (21.62) 20 (15.87) 0.04
Clopidogrel 46 (88.46) 33 (44.59) 79 (62.70) 0.001
Ticagrelor 1 (1.92) 0 (0) 1 (0.79) 0.23
ASA 51 (98.08) 65 (87.84) 116 (92.06) 0.04
Nitrate 4 (7.69) 11 (14.86) 15 (11.9) 0.22
CCB 8 (15.38) 31 (41.89) 39 (30.95) 0.002
Fibrate 0 (0) 1 (1.35) 1 (0.79) 0.4
Loop diuretic 16 (30.77) 9 (12.16) 25 (19.84) 0.02
Diuretic 5 (9.62) 21 (28.38) 26 (20.63) 0.01
MRA 18 (34.62) 9 (12.16) 27 (21.43) 0.003
Statin 49 (94.23) 64 (86.49) 113 (89.68) 0.16
Metformin 9 (17.31) 48 (64.86) 57 (45.24) 0.001
Insulin 7 (13.46) 32 (43.24) 39 (30.95) 0.001
Acarbose 0 (0) 3 (4.05) 3 (2.38) 0.14
DPP‑4 inhibitor 0 (0) 1 (1.35) 1 (0.80) 0.41
Sulphonylurea 4 (7.69) 31 (41.89) 35 (27.78) 0.001
Data are presented as number (percentage) or median (interquartile range) unless otherwise indicated.
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; BP, blood pressure; 
CCB, calcium channel blocker; DPP‑4, dipeptidyl peptidase 4; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist
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a reduction of SFA intake to less than 10% of total 
energy, through replacement by PUFAs.26 It was 
calculated that the risk of coronary artery disease 
(CAD) is reduced by 2% to 3% when 1% of energy 
intake from SFAs is replaced by PUFAs.26,27 It was 
also shown that even isocaloric replacement of 
SFAs with PUFAs resulted in a reduction of LDL ‑C 
levels and the ratio of TC to HDL ‑C levels, which 
are established risk factors for CAD.28 A recent 
the dietary intake of FAs during the previous 
weeks. However, in addition to diet, the FA con‑
centration is determined by endogenous FA me‑
tabolism including FA synthesis, desaturation, 
elongation, retroconversion, and oxidation.6,24,25
saturated fatty acids The current European 
Society of Cardiology guidelines on cardiovascular 
disease prevention in clinical practice recommend 
Table 3 Fatty acid composition of serum phospholipids in the study groups
Variables MI group (n = 52) Control group (n = 74) P value
SFAs, μmol/l C12:0 (lauric) 2.23 (1.01–4.03) 2.06 (1.31–3.22) 0.74
C14:0 (myristic) 20.16 (13.17–26.56) 16.64 (14.65–19.52) 0.05
C16:0 (palmitic) 1080.92 (954.22–1294.80) 949.92 (857.51–1073.60) 0.001
C18:0 (stearic) 477.65 (407.48–554.74) 418.61 (349.10–489.05) 0.02
C24:0 (lignoceric) 29.52 (23.40–35.09) 24.48 (20.29–29.42) 0.003
n‑7 MUFAs C16:1 (palmitoleic) 20.33 (14.02–30.38) 14.93 (12.11–21.08) 0.006
n‑9 MUFAs C18:1 (oleic) 329.58 (279.81–415.52) 276.71 (244.13–334.06) 0.001
n‑3 PUFAs, μmol/l C18:3 (α ‑linolenic) 8.85 (5.20–11.88) 6.45 (4.84–8.86) 0.01
C20:5 (EPA) 46.17 (31.72–82.03) 62.17 (44.57–81.29) 0.10
C22:6 (DHA) 261.52 (222.06–353.39) 285.51 (236.01–337.17) 0.41
n‑6 PUFAs, μmol/l C18:2 (linoleic) 556.93 (465.59–653.24) 438.84 (373.24–534.49) 0.001
C20:2 (EDA) 20.03 (15.40–24.89) 16.82 (13.54–20.89) 0.01
C20:4 (arachidonic) 533.52 (437.18–612.34) 535.12 (460.67–621.50) 0.46
Data are presented as median (interquartile range).
Abbreviations: DHA, docosahexaenoic acid; EDA, eicosadienoic acid; EPA, eicosapentaenoic acid; MUFAs, monounsaturated acids; PUFAs, polyunsaturated fatty acids; 
SFAs, saturated fatty acids; others, see TAble 1
Table 2 Baseline laboratory test results of the study groups
Variable MI group (n = 52) Control group (n = 74) Total population (n = 126) P value
Creatinine, µmol/l 87 (73.25–107) 84 (77–93.25) 84 (75.5–94.25) 0.28
hs ‑TnT, µg/l 1.39 (0.25–5.76) – – –
HbA1c, % – 7 (6.6–7.5) – –
Glucose, mmol/l 6.9 (5.73–10.8) – – –
TC, mmol/l 4.96 (4.33–5.79) 3.77 (3.22–4.34) 4.21 (3.44–5.1) 0.001
LDL ‑C, mmol/l 3.44 (2.71–4) 1.92 (1.52–2.65) 2.55 (1.74–3.39) 0.001
HDL ‑C, mmol/l 1.27 (1.08–1.65) 1.23 (0.98–1.45) 1.24 (1.02–1.56) 0.13
TG, mmol/l 1.06 (0.74–1.56) 1.38 (1.12–1.92) 1.26 (0.95–1.84) 0.005
AST, U/l 49 (29.50–91) 19 (16–23) 23 (18–32) 0.001
ALT, U/l 29.5 (24.75–40.25) 22 (14–28) 25 (17–33.75) 0.001
hs ‑CRP, mg/l 4.46 (1.90–12.85) 1.6 (0.74–2.77) 2.12 (1.13–5.59) 0.001
eGFR, ml/min 75 (56.25–89.25) 78 (69.25–89.18) 78 (63.75–89.18) 0.21
Data are presented as median (interquartile range).
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; eGFR, estimated glomerular filtration rate (Modification of Diet in Renal Disease formula); HbA1c, 
glycated hemoglobin A1c; HDL‑C, high‑density lipoprotein cholesterol; hs ‑CRP, high ‑sensitivity C ‑reactive protein; hs ‑TnT, high ‑sensitivity troponin T; LDL ‑C, low ‑density 
lipoprotein cholesterol; TC, total cholesterol; others, see TAble 1
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prospective data with regard to CAD risk are 
limited and remain controversial.30 ‑33 It was 
found that the total intake of MUFAs is signif‑
icantly inversely correlated with total mortali‑
ty, but no association with CAD was observed.34 
Some authors underline the role of MUFA or‑
igin for their impact on CVDs.31 The replace‑
ment of SFAs with plant ‑based MUFAs was as‑
sociated with a significantly lower risk of CAD 
when compared with animal ‑based MUFAs.31 
Some epidemiologic evidence suggests that 
the length of carbon chains in MUFAs might 
play a role in the prediction of CVDs.35 Li et al35 
demonstrated that the higher concentrations 
of long ‑chain (14–18 carbon atoms) MUFAs 
analysis of EPIC ‑Norfolk and EPIC ‑Denmark co‑
horts by Praagman et al29 suggested that a higher 
consumption of C4:0–C10:0, C12:0, and C14:0 was 
associated with a lower MI risk. The conflicting ev‑
idence on the association between SFAs and CAD 
could be due to differences in the types of SFAs, 
based on their carbon ‑atom chain lengths.29 In 
our study, the majority of SFAs were inversely cor‑
related with MI; however, the levels of lauric acid 
(C12:0), with the longest carbon‑atom chain in our 
study, were similar between groups.
Monosaturated fatty acids Intervention‑
al studies demonstrated that MUFAs could 
improve cardiovascular risk factors, but 
Table 4 Univariate and multivariate logistic regression analyses of predictors of myocardial infarction
Variable Univariate analysis Multivariate analysis (AUC, 0.99)
OR (95% CI) P value AUC OR (95% CI) P value
Weight, kg 0.97 (0.945–0.993) 0.01 0.67 – –
Waist circumference, cm 0.956 (0.924–0.987) 0.0046 0.66 – –
BMI, kg/m2 0.856 (0.773–0.940) 0.0008 0.70 0.24 (0.2–0.56) <0.0001
Creatinine, µmol/l 1.016 (1.001–1.034) 0.02 0.56 – –
Heart failure, n (%) 3.535 (1.189–11.559) 0.02 0.65 – –
Type 2 diabetes, n (%) 0.0039 (0.00003–0.03)a <0.0001 0.82 – –
LVEF, % 0.883 (0.805–0.949) 0.0001 0.78 – –
Diastolic BP, mmHg 1.031 (1.004–1.062) 0.03 0.60 – –
Hypercholesterolemia 12 (3.32–77.158) <0.0001 0.64 – –
Hypertriglyceridemia 0.227 (0.079–0.568) 0.001 0.62 – –
TC, mmol/l 2.766 (1.873–4.334) 0.0001 0.78 – –
LDL ‑C, mmol/l 3.759 (2.373–6.438) 0.0001 0.82 2.34 (1.32–10.26)b <0.0001
TG, mmol/l 0.618 (0.36–0.995) 0.048 0.65 – –
AST, U/l 1.284 (1.164–1.463) 0.0001 0.95 1.92 (1.26–5.03) <0.0001
ALT, U/l 1.08 (1.041–1.129) 0.0001 0.76 – –
hs ‑CRP, mg/l 1.099 (1.035–1.199) 0.0001 0.75 1.35 (1.04–2.40) 0.001
C14:0 (myristic), μmol/l 1.066 (1.016–1.126) 0.009 0.60 – –
C16:0 (palmitic), μmol/l 1.003 (1.001–1.004) 0.002 0.67 – –
C18:0 (stearic), μmol/l 1.004 (1.001–1.008) 0.02 0.62 – –
C24:0 (lignoceric), μmol/l 1.076 (1.027–1.133) 0.002 0.66 – –
C16:1 (palmitoleic), μmol/l 1.051 (1.017–1.091) 0.003 0.64 1.48 (1.13–2.61) 0.001
C18:1 (oleic), μmol/l 1.008 (1.004–1.014) 0.0002 0.69 – –
C18:2 (linoleic), μmol/l 1.006 (1.003–1.01) 0.0001 0.73 – –
C18:3 (α ‑linolenic), μmol/l 1.091 (1.006–1.194) 0.03 0.63 – –
C20:2 (EDA), μmol/l 1.078 (1.018–1.145) 0.01 0.63 0.32 (0.05–0.68) <0.0001
Total SFAs μmol/l 1.002 (1.001–1.003) 0.003 0.66 – –
Total n‐6 PUFAs μmol/l 1.002 (1.000–1.004) 0.02 0.65 – –
a Values calculated with the Firth bias‑adjusted method; b Per 0.1‑unit increase
Abbreviations: AUC, area under the curve; CI, confidence interval; LVEF, left ventricular ejection fraction; OR, odds ratio; see TAbleS 1, 2, and 3
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Figure 1 Distribution of fatty acid composition in serum phospholipids in patients in the acute phase of myocardial infarction (MI) and in the control group: 
a – total saturated fatty acids (SFAs); B – total monosaturated fatty acids (MUFAs); c – total n‑3 polyunsaturated fatty acids (PUFAs); d – total n‑6 (PUFAs); 
e – the ratio of n‑6 to n‑3 PUFAs; F – the ratio of eicosadienoic to arachidonic acid (EPA/AA); g – the ratio of docosahexaenoic to arachidonic acid (DHA/AA). Boxes 
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Palmitoleic and eicosadienoic acids Al‑
though previous studies have discussed the im‑
pact of POA levels on the risk and progression of 
atherosclerotic CVD,45,46 none of them analyzed 
the effect of POA in patients with MI. Palmitole‑
ic acid was found to act as a lipokine and could 
be considered as a metabolic modulator.47 Fur‑
thermore, POA was associated with decreased 
LDL ‑C and fibrinogen levels as well as increased 
HDL ‑C levels.47‑49
We did not identify any studies regarding 
the association between EDA levels and the acute 
phase of MI. Eicosadienoic acid is a naturally oc‑
curring n‑6 polyunsaturated FA and a relative‑
ly minor metabolite of LA. It can be further me‑
tabolized to, for example, AA, thereby giving it 
proinflammatory properties.50 In our study, we 
demonstrated a novel association between EDA 
levels in patients with acute phase MI.
Limitations First, the cross ‑sectional design 
of the study did not allow us to infer causality, 
and there was no follow ‑up. Second, our patients 
were provided with dietary advice regarding low‑
‑fat and low ‑carbohydrate meals, but dietary fat 
intake was not determined. Third, the higher 
presence of obesity and T2D in the control group 
could affect the inference between groups. Finally, 
the multiple logistic regression model for MI per 
1‑unit increase in EDA showed opposite results 
to those of the simple logistic regression model 
for EDA, which was confirmed also after elimi‑
nating the observations with the highest influ‑
ence on the model (Cook’s distance). This could 
be the so called Simpson’s paradox resulting from 
adjustment for known risk factors, such as LDL ‑C.
conclusions The major differences in the FA 
composition of serum phospholipids between pa‑
tients with MI and high ‑risk individuals with sta‑
ble atherosclerotic CVD and T2D were the high‑
er content of SFAs, MUFAs, n‑6 PUFAs, as well 
as the ratio of n‑6 to n‑3 PUFAs. In the multivar‑
iate analysis, apart from known cardiovascular 
risk factors, EDA and POA levels were indepen‑
dent predictors of MI.
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had a beneficial impact on all ‑cause and cardio‑
vascular mortality, while very long ‑chain MU‑
FAs (≥20 carbon atoms) contributed to higher 
mortality rates.
n‑3 Polyunsaturated fatty acids In our 
study, only the  ALA (C18:3) concentration 
was significantly higher in the MI group. We 
did not observe any significant differences be‑
tween other n‑3 PUFAs, including DHA and 
EPA. A recent systematic review of random‑
ized control trials demonstrated no beneficial 
effects of n‑3 PUFAs on mortality or cardio‑
vascular events.12 In the VITAL study (Vitamin 
D and Omega‑3 Trial; treatment with 1 g/d of 
n‑3 PUFAs) on primary cardiovascular preven‑
tion, the authors found a significant 19% reduc‑
tion of major adverse cardiovascular events, 
but only in patients with low fish consump‑
tion.36 On the contrary, the REDUCE ‑IT tri‑
al, which investigated the impact of high ‑dose 
n‑3 PUFAs (4 g/d; pure EPA ethyl ester) on es‑
tablished CVD or T2D and other cardiovascu‑
lar risk factors, demonstrated significant ben‑
efits of an intervention with n‑3 PUFAs, in‑
cluding a reduction in major adverse cardiovas‑
cular events by 25%.13 Finally, the membrane 
composition of FAs (especially EPA and DHA) 
in the inflammatory cells could alter cell func‑
tion. Therefore, the anti ‑inflammatory impact 
of those acids may contribute to their protec‑
tive actions against an atherosclerotic process 
and plaque rupture.37
n‑6 Polyunsaturated fatty acids (PUFAs) and 
the ratio of n‑6 to n‑3 PUFAs A multicenter 
trial by Nishizaki et al38 found that a low ratio 
of EPA to AA levels, but not of DHA to AA lev‑
els, was significantly associated with the occur‑
rence of MI. In our study, these ratios were sim‑
ilar in both groups. Nevertheless, we observed 
that the ratio of n‑6 to n‑3 PUFAs and total n‑6 
PUFA levels were much higher in the MI group 
than in controls.
It was reported that the LA concentration 
was inversely associated with the occurrence of 
MI.39 Moreover, it was shown that low serum 
levels of n‑6 PUFAs could predict a poor long‑
‑term prognosis in patients with acute CVD. In 
particular, decreased dihomo ‑γ‑linolenic acid 
(DGLA) levels were associated with increased 
total mortality rates in patients with acute CVD. 
However, DGLA and AA have the opposite ef‑
fects, mainly due to their metabolites. The pro‑
inflammatory effect of AA comes from the con‑
version to series‑2 prostaglandins and series‑4 
leukotrienes, which are known to induce plate‑
let aggregation, inflammation, and vasocon‑
striction.40,41 On the other hand, DGLA under‑
goes oxidative metabolism to anti ‑inflammatory 
eicosanoids (series‑1 prostaglandin and series‑3 
leukotrienes).40,42‑44
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